TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
Public ClinicalTrials.gov record NCT02322281. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
TIGER-3: A Phase 3, Open-label, Multicenter, Randomized Study of Oral Rociletinib (CO-1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC) After Failure of at Least 1 Previous EGFR-directed Tyrosine Kinase Inhibitor (TKI) and Platinum-doublet Chemotherapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare the anti-tumor efficacy of oral single-agent rociletinib, as measured by investigator assessment of the PFS, with that of single-agent cytotoxic chemotherapy in patients with EGFR-mutated, advanced/metastatic NSCLC after failure of at least 1 previous EGFR-directed TKI and at least 1 line of platinum-containing doublet chemotherapy.
Study identification
- NCT ID
- NCT02322281
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 149 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2015 (Type not available)
- Primary completion
- Mar 29, 2018 (Actual)
- Completion
- Mar 29, 2018 (Actual)
- Last update posted
- Aug 14, 2019
2015 – 2018
United States locations
- U.S. sites
- 31
- U.S. states
- 15
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Comprehensive Blood and Cancer Center | Bakersfield | California | 93309 | — |
| City of Hope Cancer Center | Duarte | California | 91010 | — |
| Saint Joseph Heritage Healthcare | Fullerton | California | 92835 | — |
| University of California San Diego Moores Cancer Center | La Jolla | California | 92093-0698 | — |
| Cancer Care Associates Medical Group, Inc. | Redondo Beach | California | 90277 | — |
| Sutter Cancer Center | Sacramento | California | 95816 | — |
| University of California, San Francisco Helen Diller Family Comprehensive Cancer Center | San Francisco | California | 94115 | — |
| Central Coast Medical Oncology Corporation | Santa Maria | California | 93454 | — |
| University of California at Los Angeles | Santa Monica | California | 90404 | — |
| Stanford University School of Medicine | Stanford | California | 94305 | — |
| The Oncology Institute of Hope and Innovation | Whittier | California | 90603 | — |
| Sylvester Comprehensive Cancer Center (UMHC) | Deerfield Beach | Florida | 33442 | — |
| University of Florida Health Science Center | Gainesville | Florida | 32608 | — |
| Memorial Healthcare System | Pembroke Pines | Florida | 33028 | — |
| Northside Hospital | Atlanta | Georgia | 30341 | — |
| North Shore University Health System | Evanston | Illinois | 60201 | — |
| Walter Reed National Military Medical Center | Bethesda | Maryland | 20889 | — |
| Saint Joseph Mercy Hospital | Ann Arbor | Michigan | 48106 | — |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Virginia Piper Cancer Institute | Minneapolis | Minnesota | 55407 | — |
| Regional Cancer Care Associates, LLC | East Brunswick | New Jersey | 08816 | — |
| Regional Cancer Care Associates | Morristown | New Jersey | 07962 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| The Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| Providence Health and Services | Portland | Oregon | 97223 | — |
| Oregon Health & Science University (OHSU) - Knight Cancer Institute | Portland | Oregon | 97239 | — |
| University of Pittsburgh Cancer Institute (UPMC) | Pittsburgh | Pennsylvania | 15232 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| University of Virginia | Charlottesville | Virginia | 22903 | — |
| Virginia Cancer Institute | Richmond | Virginia | 23230 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02322281, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 14, 2019 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02322281 live on ClinicalTrials.gov.